Biopharma Commercialization Guide
New Book Offers Strategy Guide for Navigating Biopharma Discovery and Commercialization
Anonymous
Dr. David H. Crean has released Dual Fluency: Bridging Science, Capital, and Governance in Life Sciences, a guide for biopharma leaders navigating the gap between early discovery and commercialization. The book addresses why many approved therapeutics fail to recover development costs and outlines methods for translating scientific data into investable valuations, structuring partnerships and licensing deals, and improving board-level asset management. It also discusses capital-stack strategies, including BARDA grants, royalty monetization, venture debt, and crossover investment, intended to reduce unnecessary equity dilution. The book is aimed at scientist-founders, pre-commercial executives, business development professionals, and healthcare investors, and is expected to become available through Amazon and major bookstores.
Key Points
1
The book was announced on September 17, 2026, in San Diego, California, United States.
2
Dr. David H. Crean, who holds PhD and MBA degrees, is the founder and managing partner of Cardiff Advisory LLC, a San Diego-based boutique life sciences mergers-and-acquisitions and strategic-advisory firm.
3
The article says Crean has more than three decades of experience and has closed more than 50 transactions involving mergers and acquisitions, licensing, partnering and capital raises.
4
The release describes Dual Fluency as a blueprint for biopharma companies navigating the particularly difficult transition from early discovery to commercialization, framing the problem as a multibillion-dollar translation gap.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
8
Articles
112
Reach
120
A
AnonymousAuthor
